Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 9 June 2021, 10:31 HKT/SGT
Share:
    

Source: Eisai
Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).

Eisai considers neurology a therapeutic area of focus. Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

For more information, visit https://www.eisai.com/news/2021/news202143.html.


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
June 18, 2021 14:02 HKT/SGT
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
June 15, 2021 08:00 HKT/SGT
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
June 9, 2021 12:44 HKT/SGT
Eisai Receives Special Prize at Platinum Career Award 2021
June 8, 2021 13:09 HKT/SGT
Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM
June 8, 2021 08:47 HKT/SGT
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's disease treatment to address a defining pathology of the disease
June 8, 2021 07:19 HKT/SGT
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib
May 31, 2021 17:54 HKT/SGT
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
May 20, 2021 08:36 HKT/SGT
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting
May 19, 2021 11:27 HKT/SGT
Anticancer Agent "Remitoro Intravenous Drip Infusion 300 microgram" (Denileukin Diftitox (Genetical Recombination)) Launched in Japan
May 14, 2021 16:48 HKT/SGT
Eisai and National Cancer Center Commence Joint Research and Development Project
More news >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: